SomatoKine User Fee Goal Date Extended to Oct. 3, Insmed Says
This article was originally published in The Pink Sheet Daily
Executive Summary
The insulin-like growth factor therapy is under priority review for the orphan indication of growth hormone insensitivity syndrome. The original review deadline of July 3 is being extended to allow FDA time to review a major amendment to the NDA.
You may also be interested in...
Insmed iPlex Growth Agent “Approvable” Letter Leaves Orphan Status Issue Open
Exclusivity discussions with Office of Orphan Products Development are ongoing, CEO Geoffrey Allan says Sept. 28; letter requests chemistry, manufacturing and controls data.
Insmed iPlex Growth Agent “Approvable” Letter Leaves Orphan Status Issue Open
Exclusivity discussions with Office of Orphan Products Development are ongoing, CEO Geoffrey Allan says Sept. 28; letter requests chemistry, manufacturing and controls data.
Tercica’s Growth Treatment Increlex Clears FDA With Orphan Drug Exclusivity
The company plans to launch the extreme short stature therapy in January with a 30-member sales force.